Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fr-122047 SCHEMBL9548002 | 0.99 | PTGS2 (0.98) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| Fr-122047 SCHEMBL15531779 | 0.98 | PTGS2 (0.95) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL9548056 | 0.90 | ALDH1A1 (0.82) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL9548082 | 0.88 | PTGS2 (0.79) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL9548039 | 0.88 | PTGS2 (0.78) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL9548105 | 0.87 | PTGS2 (0.77) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL9548091 | 0.87 | ALDH1A1 (0.77) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| Hydrochloric Acid SCHEMBL9547997 | 0.87 | PTGS2 (0.76) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| Hydrochloric Acid SCHEMBL9547994 | 0.86 | PTGS2 (0.75) | PTGS2ALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL9548040 | 0.84 | PTGS2 (0.72) | PTGS2ALDH1A1KDM4EKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12194020-B2 | Reversing baldness through cannabinoid receptor activation | POSTREL RICHARD (US) | 2025-01-14 | — | — | US | claimed |
| CN-118079006-A | Skin composition | 国立大学法人东京医科齿科大学 | 2024-05-28 | — | — | CN | claimed |
| US-20230115675-A1 | METHODS OF TREATING CANCER | BROAD INST INC (US) | 2023-04-13 | — | — | US | claimed |
| CN-115917324-A | Methods of treating cancer | 布罗德研究所有限公司 | 2023-04-04 | — | — | CN | claimed |
| EP-4111202-A1 | METHODS OF TREATING CANCER | The Broad Institute Inc. (US) | 2023-01-04 | — | — | EP | claimed |
| US-20220331389-A1 | SKIN COMPOSITION | EADERM CO., LTD. (JP) | 2022-10-20 | — | — | US | claimed |
| US-20220249434-A1 | Reversal of Baldness in Men and Women through Cannabinoid Receptor Activation | POSTREL RICHARD (US) | 2022-08-11 | — | — | US | claimed |
| US-20220117884-A1 | Methods and Compostitions for Enhancing the Viability of Microneedle Pores | STINCHCOMB AUDRA LYNN (US) | 2022-04-21 | — | — | US | claimed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | claimed |
| US-5217971-A | Anticoagulants, hypotensive agents, antiallergens and antiinflammatory agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-08 | — | — | US | claimed |
| EP-0377457-A1 | Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-07-11 | — | — | EP | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090492-A1 | TUMOR-ACTIVATED CELL ENGAGERS AND METHODS OF USE THEREOF | Xilio Development, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | XILIO DEV INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-5217971-A | Anticoagulants, hypotensive agents, antiallergens and antiinflammatory agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0377457-A1 | Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115675-A1 | METHODS OF TREATING CANCER | SOD1, RNASE1, COXFA4L2 | PTGS2 1378/4885ALDH1A1 727/4885KDM4E 3064/4885 |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | PTGS2 2406/4885ALDH1A1 3836/4885KDM4E 2989/4885 |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | PTGS2 4/4885ALDH1A1 953/4885KDM4E 3590/4885 |
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | SPPL2B, SPPL2A, CTSL | PTGS2 2186/4885ALDH1A1 2254/4885KDM4E 2739/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | PTGS2 2609/4885ALDH1A1 3382/4885KDM4E 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.